Business Wire

THALES

20.3.2024 09:01:32 CET | Business Wire | Press release

Share
2024 Thales Data Threat Report Reveals Rise in Ransomware Attacks, as Compliance Failings Leave Businesses Vulnerable to Breaches

Thales today announced the release of the 2024 Thales Data Threat Report, its annual report on the latest data security threats, trends, and emerging topics based on a survey of nearly 3000 IT and security professionals in 18 countries across 37 industries. This year’s report found that 93% of IT professionals believe security threats are increasing in volume or severity, a significant rise from 47% last year.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240320217738/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

©Thales

Threats continue to increase in volume and severity

The number of enterprises experiencing ransomware attacks surged by over 27% in the past year. Despite this escalating threat, less than half of organisations have a formal ransomware plan in place, with 8% resorting to paying the ransom demands.

Malware stands out as the fastest-growing threat of 2024, with 41% of enterprises witnessing a malware attack in the past year – closely followed by phishing and ransomware. Cloud assets, including SaaS applications, cloud-based storage, and cloud infrastructure management, remain the primary targets for such attacks.

The report shows that for a second year running, human error remains the leading cause of data breaches, with 31% of enterprises pinpointing this as the root cause.

These insights are drawn from the 2024 Thales Data Threat Report, conducted by 451 Research. The report sheds light on how businesses are adapting their data security strategies and practices in response to an evolving threat landscape.

Compliance is the key to data security

The research found that over two fifths (43%) of enterprises failed a compliance audit in the past twelve months – with the report highlighting a very clear correlation between compliance and data security.

Of those that had failed a compliance audit in the past twelve months, 31% had experienced a breach that very same year. This compares to just 3% of those who had passed compliance audits.

Operational complexity continues to cause data headaches

Fundamental understanding of what systems, applications, and data are at risk continue to lag due to changing regulatory and threat landscapes. Only a third (33%) of organisations are able to fully classify all of their data, with a worrying 16% stating that they classify very little or none of their data.

Operational complexity remains a barrier. While the number of respondents reporting five or more key management systems is down (53% versus 62% last year), the average number declined only slightly (from 5.6 to 5.4).

The reality of multicloud across services and changing global data privacy regulations means that data sovereignty is a leading priority for businesses, with 28% identifying mandatory external key management as the leading way to achieve sovereignty. 39% said that data residency would no longer be an issue provided that external encryption, key management, and separation of duties were implemented.

“Enterprises need to know exactly what they’re trying to protect. With global data privacy regulations continually changing, they need to have good visibility across their organization to stand any chance of staying compliant,” said Sebastien Cano, Senior Vice President at Thales Cloud Protection and Licensing.

“If there’s one key takeaway from this year’s study, it’s that compliance is key. In fact, companies that had a good hold over their compliance processes and passed all their audits were also less likely to suffer a breach. We’ll start to see more compliance and security functions coming together. This would be a huge positive step to strengthen cyber defenses and build trust with customers,” he added.

Emerging technology poses both threats and opportunities

Looking ahead, the report also explored which emerging technologies are top-of-mind for IT and security professionals, with 57% identifying Artificial Intelligence (AI) as a huge source of concern. This was closely followed by IoT (55%) and Post Quantum Cryptography (45%).

That said, enterprises are also looking at the opportunities that emerging technologies bring, with over a fifth (22%) planning to integrate Generative AI into their security products and services in the next 12 months, and a third (33%) planning to experiment integrating the technology.

For more information please join our webinar with S&P Global on April 16, 2024 hosted by Eric Hanselman, Chief Analyst and Justin Lam, Research Analyst.

About the 2024 Thales Global Data Threat Report
The 2024 Data Threat Report (DTR) analyzes how core security practices have changed in response to or in anticipation of changing threats. This report also offers perspectives on what organizations can do to leverage data assets to expand opportunities to make their businesses more agile and build trust with their customers. This research was based on a global survey of 2,961 respondents fielded via web survey with targeted populations for each country, aimed at professionals in security and IT management. In addition to criteria about level of knowledge on the general topic of the survey, the screening criteria for the survey excluded those respondents who indicated affiliation with organizations with annual revenue of less than US$100 million and with US$100 million-$250 million in Australia, Brazil, Canada, France, Germany, Hong Kong, India, Italy, Japan, Mexico, the Netherlands, New Zealand, South Korea, Singapore, Sweden, the United Arab Emirates, the United Kingdom and the United States of America.

About Thales

Thales (Euronext Paris: HO) is a global leader in advanced technologies within three domains: Defence & Security, Aeronautics & Space, and Digital Identity & Security. It develops products and solutions that help make the world safer, greener and more inclusive.

The Group invests close to €4 billion a year in Research & Development, particularly in key areas such as quantum technologies, Edge computing, 6G and cybersecurity.

Thales has 81,000* employees in 68 countries. In 2023, the Group generated sales of €18.4 billion.

* These figures exclude the ground transportation business, which is being divested

PLEASE VISIT

Thales Group

Cloud Protection & Licensing Solutions | Thales Group

Cybersecurity Solutions | Thales Group

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240320217738/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States1.4.2026 13:30:00 CEST | Press release

-With this expansion, any variant that results in production of CFTR protein is now included in the indication for ALYFTREK and TRIKAFTA, reinforcing the impact these medicines have, regardless of the location of the variant in the CFTR protein--Approximately 800 more people with CF in the US are now eligible for a CFTR modulator for the first time- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 and older with a variant in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. Additionally, the U.S. FDA has also expanded the indication statement for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in patients ages 2 and older. This label expansion was supported b

Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer1.4.2026 13:30:00 CEST | Press release

A Landmark Registrational Study Aiming to Redefine Outcomes in MSS mCRC Which Represents Approximately 95% of Metastatic Colorectal Cancer CasesColorectal Cancer Has Become the Leading Cause of Cancer-related Death in Adults Under Age 50 Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the first patient has been enrolled in the landmark global phase 3 BATTMAN (CO.33) trial (NCT07152821). This study is evaluating Agenus’ immunotherapy combination of botensilimab (BOT) plus balstilimab (BAL) versus best supportive care in patients with refractory, unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC), a population long considered resistant to immunotherapy. This study is being conducted as a cooperative group trial led by the Canadian Cancer Trials Group (CCTG) from Canada and run across Canada, France, Australia and New Zealand. More than 100 sites will participate across the academic cooper

Klarna Agrees to $1.7 Billion Transaction Supporting up to $40B+ of Lending1.4.2026 13:19:00 CEST | Press release

Klarna, the global digital bank and flexible payments provider, has entered into a new capital efficiency transaction in the form of a Significant Risk Transfer (SRT), covering $1.7 billion-worth of Euro denominated loans and freeing up capital to support continued growth. Klarna has entered into a three-year agreement with a consortium led by Värde Partners. This is Klarna's sixth SRT transaction and improves how effectively Klarna deploys its capital on a global basis. "Our banking license is one of our biggest competitive advantages," said Niclas Neglén, Klarna's Chief Financial Officer. "This is our largest and most efficient SRT transaction to date. These transactions allow us to maximize every unit of capital to support our continued momentum." The transaction follows Klarna’s recently announced $2 billion facility supporting $17B of US Financing expansion. About Klarna Klarna is a global digital bank and flexible payments provider. With over 118 million global active Klarna user

Americhem Launches nDryve™: PFAS-Free In-Melt Technology Platform for Functional Fibers1.4.2026 13:00:00 CEST | Press release

Americhem, Inc., a global polymer solutions provider, today announced the launch of nDryve™, a PFAS-free, in-melt surface-modifying technology platform designed to deliver durable multi-fluid repellency against alcohol and other low-surface-energy fluids in fiber systems. As global regulations accelerate the phase-out of per- and polyfluoroalkyl substances (PFAS), manufacturers are under increasing pressure to maintain barrier performance without fluorinated chemistries. nDryve™ was developed to address this shift, offering a PFAS-free, in-melt alternative to conventional surface applied treatments. Engineered for Performance Without PFAS Often referred to as “forever chemicals,” PFAS have come under heightened regulatory scrutiny due to their persistence and potential environmental and health impacts. nDryve™ integrates directly into the polymer during melt processing, embedding surface-modifying functionality within the fiber matrix rather than relying on removable finishes. By engin

Biocytogen and Sihuan Pharmaceutical Announce Strategic Partnership in Weight Loss and Beyond1.4.2026 13:00:00 CEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a strategic partnership with Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan Pharmaceutical; HKEX: 00460). Under the agreement, both parties will combine Biocytogen’s leading fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive capabilities in drug development, manufacturing, and commercialization. The collaboration will focus on advancing innovative therapies across multiple disease areas, including weight loss, leveraging complementary strengths to drive synergies and establish a long-term strategic partnership. Sihuan Pharmaceutical highly values the strength of Biocytogen’s technology platforms. In this collaboration, Biocytogen will leverage its integrated platforms, including proprietary target-humanized mouse models and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye